Company profile
TENAX THERAPEUTICS, INC.
NASDAQ:TENXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| LEVOSIMENDAN | phase3 | — | 3 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03541603 | phase2 | completed | 2018-11-14 | 2020-04-07 | Tenax Therapeutics, Inc. | Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF |
| NCT07288398 | phase3 | recruiting | 2026-03-03 | 2028-06-30 | Tenax Therapeutics, Inc. | LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 |
| NCT05983250 | phase3 | active_not_recruiting | 2024-01-10 | 2026-06-30 | Tenax Therapeutics, Inc. | LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF |
| NCT02025621 | phase3 | completed | 2014-07-01 | 2016-11-01 | Tenax Therapeutics, Inc. | Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass |
| NCT07436689 | phase3 | enrolling_by_invitation | 2026-03-13 | 2029-03-01 | Tenax Therapeutics, Inc. | Long-Term Open-Label Extension Study of Oral Levosimendan |
FDA applications (0)
No records yet.